Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Pyott David E I Exercises Tarsus Options, Holds 9,575 Shares

Pyott David E I exercised options tied to Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) on 15 September 2026, leaving him with 9,575 shares. The transaction represented about 2.1% of his resulting share holding.

Vinay Lochav | 18 September 2026

Theravance Biopharma Insider Sells 13,314 Shares at $17.03

Three Transactions at $17.03 Per Share

Vinay Lochav | 18 September 2026

Travere Therapeutics Insider Exercises 32,395 Options at $8.93

Travere Therapeutics, Inc. is a biotechnology company. Inrig Jula exercised options covering 32,395 shares at $8.93 per share, a transaction that left Jula with 145,165 shares. The transaction took place on 15 September 2026 and carried SEC transaction code M.

Vinay Lochav | 18 September 2026

KIORA PHARMACEUTICALS (NASDAQ: KPRX) Reports 5.8% Passive Stake

KIORA PHARMACEUTICALS INC. (NASDAQ: KPRX) is a Pharmaceuticals: Major company. Baselake Partners, LP, Baselake Management, LLC and David Paolella report shared voting and dispositive power over 257,500 Kiora common shares, a position identified as passive.

Vinay Lochav | 18 September 2026

Medtronic (NYSE: MDT) Launches 225.4 Million-Share MiniMed Exchange Offer

The offer began on September 14, while a subsequent correction changed the timing applicable to guaranteed-delivery tenders.

Vinay Lochav | 18 September 2026

MYRIAD GENETICS INC (NASDAQ: MYGN) Awards 257,731 Shares at $0

Sikri Vishal, the company’s EVP, Commercial, received 257,731 MYRIAD GENETICS INC (NASDAQ: MYGN) shares at $0 per share on September 16, 2026. The transaction increased his reported ownership to 351,224 shares, with the award accounting for about 73.4% of that resulting position. The award …

Vinay Lochav | 18 September 2026

Fennec Pharmaceuticals (NASDAQ: FENC) Reports 24.0% Hearing Loss in Japan Study

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a biotechnology company. On September 17, 2026, the company reported ASHA-defined hearing loss in 24.0% of patients in its Japan study, compared with a prespecified historical benchmark of 56.4% and P=0.001. The primary endpoint was met, with no …

Vinay Lochav | 18 September 2026

Guardant Health (NASDAQ: GH) Director Sells 6,674 Shares at $174.46-$177.48

Director Steve E. Krognes sold 6,674 shares in four transactions on 16 September 2026, with prices ranging from $174.46 to $177.48 per share. The transactions left Krognes with 7,906 shares, and the sold amount represented about 45.8% of his prior shares holding.

Vinay Lochav | 18 September 2026

Guardant Health (NASDAQ: GH) Director Sells 826 Shares at $175

Director Azar Alex M II sold 826 Guardant Health (NASDAQ: GH) shares at $175 per share. The transaction represented about 50.0% of the director’s prior holding.

Vinay Lochav | 18 September 2026

HeartSciences (NASDAQ: HSCS) Sets September 21 Leadership Handover With Fortitude Deal Pending

Fortitude will appoint Jaime Leverton as chief executive officer on September 21, while Andrea Childs transitions to chief operating officer. The proposed combination would see Leverton lead the combined business after closing, with HeartSciences (NASDAQ: HSCS) expected to become Fortitude Mining Group, Inc.

Vinay Lochav | 18 September 2026
Support

Hi! How can we help you today?

Loading…